ANALIZA OPĆEG PREŽIVLJENJA BOLESNIKA S KARCINOMOM PLUĆA PRIJE UVOĐENJA INHIBITORA TIROZIN KINAZE I IMUNOTERAPIJE U REPUBLICI HRVATSKOJ – STUDIJA IZ JEDNE USTANOVE

Autor: JUKICA, LUKA, SEKOVSKI, BUDIMIR, ŠIMUNDŽA, IVAN, MLADINOV, SUZANA, ČAPKUN, VESNA, GLAVINA DURDOV, MERICA
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske
Volume 75
Issue 4
ISSN: 1848-8897
1330-0164
Popis: We analyzed outcome in patients with lung cancer (LC) in the period before the introduction of tyrosine kinase inhibitors and immunotherapy in the Republic of Croatia in comparison to similar studies abroad and created a basis for future analysis. At the Pathology Department, Split University Hospital Center, 1165 patients were diagnosed with LC during the 2012-2016 period. Data on age, gender, biopsy specimen, histologic type, and stage of disease were collected. Overall survival of each patient was calculated from the date of biopsy until death or the last day of follow-up.There were 74% of male and 26% of female patients. Median age was 66 years, younger than in other similar studies. In 78% of patients, the diagnosis of LC was based on brochoscopic biopsy. Adenocarcinoma (ADC) was diagnosed in 42.9%, squamous cell carcinoma (SCC) in 32.7%, and small cell lung carcinoma (SCLC) in 16.7% of cases. In females, ADC was more common than SCC (p
Analizirali smo ishod ispitanika s karcinomom pluća u razdoblju prije uvođenja inhibitora tirozin kinaze i imunoterapije u Republici Hrvatskoj, rezultate usporedili sa sličnim studijama i stvorili osnovu za buduće analize. Na Odjelu za patologiju KBC-a Split od 2012. do 2016. godine karcinom pluća je dijagnosticiran u 1165 bolesnika. Prikupljeni su podatci o dobi, spolu, bioptičkom uzorku, histološkom tipu karcinoma i stadiju bolesti. Ukupno preživljenje za svakog bolesnika izračunato je od datuma biopsije do datuma smrti, odnosno posljednjeg dana praćenja. Sedamdesetčetiri posto ispitanika bili su muškarci, a 26 % žene, medijan dobi 66 godina (manji nego u sličnim studijama). U 78 % slučajeva dijagnoza je postavljena bronhoskopskom biopsijom. Adenokarcinom (ADC) je dijagnosticiran u 42,9 %, skvamozni karcinom (SCC) u 32,7 % i karcinom malih stanica (SCLC) u 16,7 % slučajeva. U žena je ADC bio češći od SCC (p
Databáze: OpenAIRE
Externí odkaz: